Rocket Science Health US Corp.
Develops investigational intranasal drug delivery technologies that target the olfactory region to enable direct-to-brain delivery. The organization combines fluidics engineering, human factors design, preclinical and in-human testing, biomarker sampling, and delivery-verification software. The company pursues partnerships and licensing with CDMOs and pharmaceutical developers and holds issued U.S. patents covering methods and devices for precision intranasal delivery.
Industries
N/A
Nr. of Employees
small (1-50)
Rocket Science Health US Corp.
Victoria, British Columbia (headquarters stated on site)
Products
Investigational olfactory‑targeting intranasal device
A needle-free, self-guided intranasal device engineered to position a dispensing tip past the nasal valve and eject a laminar liquid stream for targeted delivery to olfactory subregions.
Investigational olfactory‑targeting intranasal device
A needle-free, self-guided intranasal device engineered to position a dispensing tip past the nasal valve and eject a laminar liquid stream for targeted delivery to olfactory subregions.
Services
Non-exclusive licensing and partner identification for device integration, clinical development, and commercialization with pharmaceutical and biotech developers.
Formative and evaluative human factors studies to validate device fit, comfort, and intuitive operation across diverse nasal anatomies and user abilities.
Integration of biomarker diagnostics and software tools to support proof-of-delivery and therapy monitoring alongside device use.
Non-exclusive licensing and partner identification for device integration, clinical development, and commercialization with pharmaceutical and biotech developers.
Formative and evaluative human factors studies to validate device fit, comfort, and intuitive operation across diverse nasal anatomies and user abilities.
Integration of biomarker diagnostics and software tools to support proof-of-delivery and therapy monitoring alongside device use.
Expertise Areas
- Intranasal drug delivery
- Direct-to-brain (olfactory) delivery
- Fluidics engineering for medical devices
- Human factors and usability testing
Key Technologies
- Laminar fluid ejection (LFE)
- Olfactory‑targeting intranasal device geometry
- 3D-printed nasal anatomical models
- Preclinical PET imaging
News & Updates
Announcement of U.S. Patent No. 12,403,275 covering fluid dynamics methods for precision intranasal drug delivery to nasal subregions including the olfactory region.
Preclinical PET imaging study demonstrating that olfactory-targeted delivery increases brain uptake for certain compounds compared to intranasal and intravenous routes.
Evaluative human factors study reporting universal fit, comfort, and intuitive operation across a broad range of adult nasal anatomies.
Partnership announcement with a global CDMO to identify partners and support development and commercial readiness of an olfactory-targeting intranasal platform.
Proof-of-concept study (peer‑reviewed) describing benchtop and in-human imaging tests that demonstrate focal deposition to the olfactory cleft using laminar fluid ejection.
Summary of peer-reviewed research showing superior preservation of mRNA/SaRNA LNP formulations and higher delivered dose yield with laminar fluid ejection compared to conventional devices.
Announcement of U.S. Patent No. 12,403,275 covering fluid dynamics methods for precision intranasal drug delivery to nasal subregions including the olfactory region.
Preclinical PET imaging study demonstrating that olfactory-targeted delivery increases brain uptake for certain compounds compared to intranasal and intravenous routes.
Evaluative human factors study reporting universal fit, comfort, and intuitive operation across a broad range of adult nasal anatomies.
Partnership announcement with a global CDMO to identify partners and support development and commercial readiness of an olfactory-targeting intranasal platform.
Proof-of-concept study (peer‑reviewed) describing benchtop and in-human imaging tests that demonstrate focal deposition to the olfactory cleft using laminar fluid ejection.
Summary of peer-reviewed research showing superior preservation of mRNA/SaRNA LNP formulations and higher delivered dose yield with laminar fluid ejection compared to conventional devices.